Not against BP, we will most likely complement what they have in their pipelines. We compete with other non commercial preclinical research labs and smaller biotechs. We were in the same boat now as we were with with HepC development, BP will have their own tech but probably require further IP from smaller operations such as Gilead did with sofosbuvir. It's competitive.
